Inflammatory breast cancer: Current understanding

Current Opinion in Oncology

Volumn 18, Issue 6, 2006, Pages 563-571

  Dirix, Luc Y ^a,b   Dam, Peter Van ^a   Prové, Annemie ^a   Vermeulen, Peter B ^a  

^a Oncology Centre of Antwerp   (Belgium)

^b NONE   (Belgium)

Author keywords

Expression profiling; Inflammatory breast cancer; Locally advanced breast cancer

Indexed keywords

CHEMOKINE RECEPTOR; PROTEIN P53; STEROID RECEPTOR; UVOMORULIN;

ADVANCED CANCER; ANGIOGENESIS; BONE MARROW METASTASIS; BREAST CANCER; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; INFLAMMATORY BREAST CANCER; INFLAMMATORY DISEASE; LYMPHANGIOGENESIS; MICROARRAY ANALYSIS; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR EMBOLISM; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; HUMANS; INFLAMMATION; TUMOR MARKERS, BIOLOGICAL;

EID: 33748895214     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cco.0000245307.29026.0a     Document Type: Review

References (61)

1. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10:1014-1024.
2. Kleer CG, van Golen KL, Merajver SD. Molecular biology of breast cancer metastasis: inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2000; 2:423-429.
3. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol 2003; 21:2254-2259.
4. Levine PH, Steinhorn SC, Ries LG, Aron JL. Inflammatory breast cancer: the experience of the Surveillance, Epidemiology, and End Results (SEER) program. J Natl Cancer Inst 1985; 74:291-297.
5. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma incidence and survival: the Surveillance Epidemiology, and End Results Program of the National Cancer Institute, 1975-1992. Cancer 1998; 82:2366-2372.
6. Hance KW, Anderson WF, Devesa SS, et al. Trends in inflammatory breast carcinoma incidence and survival: the Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute. J Natl Cancer Inst 2005; 97:966-975. In this extensive analysis of the SEER database on 180 224 patients with breast cancer between 1988 and 2000, a relative increase in the diagnosis of IBC in comparison with other types of LABC is observed. The racial distribution, estrogen receptor status and survival data confirm previous results.
7. Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol 2004; 22:4067-4074.
8. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence rate patterns for different histopathological types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13:1128-1135.
9. Bertucci F, Finetti P, Cervera N, et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 2006; 66:4636-4644. An analysis of genome-wide transcription profiling of 22 cases of medullary breast cancer, some distinct features are observed, but on the whole a profile similar to that of the basal subgroup is evident. This suggests that medullary breast cancer is a distinct subgroup of basal breast cancer.
10. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628-3636.
11. Güth U, Moch H, Herberich L, Holzgreve W. Noninflammatory breast carcinoma with skin involvement. Cancer 2004; 100:470-478; Links.
12. Güth U, Wight E, Schötzau A, et al. Breast carcinoma with noninflammatory skin involvement (T4b). Cancer 2005; 104:1862-1870. Only in patients with a tumor over 5cm did skin involvement add significant prognostic information, according to the T4b criteria.
13. Güth U, Singer G, Schotzau A, et al. Scope and significance of nonuniform classification practices in breast cancer with non-inflammatory skin involvement: a clinicopathologic study and an international survey. Ann Oncol 2005; 16:1618-1623.
14. Güth U, Wight E, Schötzau A, et al. Correlation and significance of histopathological and clinical features in breast cancer with skin involvement (T4b). Hum Pathol 2006; 37:264-271. It is suggested that invasion of the papillary dermis rather than the epidermis is a relevant event.
15. Güth U, Singer G, Langer I, et al. T4 category revision enhances the accuracy and significance of stage II breast cancer. Cancer 2006; 106:2569-2575. In this analysis the T4a, T4b and T4c categories were eliminated and these tumors were classified only according to their T and N stage irrespective of chest wall or skin involvement.
16. Harigopal M, Berger AJ, Camp RL, et al. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer. Clin Cancer Res 2005; 11:4083-4089. After construction of a tissue microarray and with the application of an automated image analysis system, E-cadherin was shown to be similarly expressed in the primary tumor and its nodal metastasis in tissue samples from 207 patients. On univariate analysis, increased E-cadherin expression was associated with improved survival (P = 0.007).
17. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res 2001; 61:5231-5241.
18. Kleer CG, van Golen KL, Braun T, Merajver SD. Persistent E-cadherin expression in inflammatory breast cancer. Mod Pathol 2001; 14:458-464.
19. Alpaugh ML, Tomlinson JS, Shao ZM, Barsky SH. A novel human xenograft model of inflammatory breast cancer. Cancer Res 1999; 59:5079-5084.
20. Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH. Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 2002; 161:619-628.
21. Hunt NC, Douglas-Jones AG, Jasani B, et al. Loss of E-cadherin expression associated with lymph node metastases in small breast carcinomas. Virch Arch 1997; 430:285-298.
22. Colpaert CG, Vermeulen PB, Benoy I, et al. Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. Br J Cancer 2003; 88:718-725.
23. Gupta A, Deshpande CG, Badve S. Role of E-cadherins in development of lymphatic tumor emboli. Cancer 2003; 97:2341-2347.
24. Kantak SS, Kramer RH. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 1998; 273:16953-16961.
25. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353:793-802. An extensive analysis of studies on the presence of immunocytochemically defined tumor cells in bone marrow aspirates of patients with operable breast cancer confirms the prognostic significance of DTCs.
26. Benoy IH, Elst H, Van der Auwera I, et al. Real-time RT-PCR correlates with immunohistochemistry for the detection of disseminated epithelial cells in bone marrow aspirates of patients with breast cancer. Brit J Cancer 2004; 91:1813-1820.
27. Dirix L, Benoy I, Elst H, et al. Real time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Eur J Cancer Suppl 2006; 4:139.
28. Minn AJ, Gupta GP, Siegel PM, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005; 436:518-524. Individual cell derived progenies of the MDA-MB-231 human breast cancer cell line have distinct tissue tropisms and metastatic abilities. By means of in-vivo selection, genes that contribute to selective metastasis to the lung were identified.
29. Cabioglu N, Sahin A, Doucet M, et al. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow. Clin Exp Metastasis 2005; 22:39-46. In an immunohistochemical study bone marrow positivity for cytokeratin positive cells was associated with CXC4 expression in the primary tumor (P = 0.013).
30. Andre F, Cabioglu N, Assi H, et al. Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol 2006; 17:945-951. A series of 142 primary tumors of patients with nodal involvement at presentation were analyzed for the expression of four different chemokine receptors.CXCR4 was associated with an increased risk for liver metastasis (odds ratio 3.71, P = 0.005).
31. Cabioglu N, Gong Y, Sneige N, et al. Increased expression of chemokine receptors in inflammatory breast cancer: implications for novel targeted therapies. ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl):9655.
32. McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin Cancer Res 2002; 8:3857-3862.
33. Van der Auwera I, Van Laere SJ, Van den Eynden GG, et al. Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 2004; 10:7965-7971.
34. Shirakawa K, Shibuya M, Heike Y, et al. Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer. Int J Cancer 2002; 99:344-351.
35. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61:445-451.
36. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-777. This report evaluates the effects of neoadjuvant bevacizumab in patients with LABC. A striking 66.7% median decrease compared with baseline in p-VEGFR2 in tumor cells was observed. This decrease is associated with an increase in tumor cell apoptosis. These data suggest that bevacizumab therapy, at least in LABC, clearly has direct antitumor activity and confirms the widespread VEGFR2 distribution and activation in human breast cancer.
37. Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 2005; 11:7637-7642. In an extensive comparative study using four different antibodies directed against epitopes expressed on lymphatic endothelial cells, an increased fraction of proliferating lymphatic endothelial cells is observed in IBC.
38. Guerin M, Sheng Z, Andrieu N, et al. Strong association between c-myb and oestrogen receptor expression in human breast cancer. Oncogene 1990; 5:131-135.
39. Van den Eynden GG, Van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004; 85:13-22.
40. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A 1992; 89:7262-7266.
41. Riou G, Le MG, Travagli JP, et al. Poor prognosis of p53 gene mutations and overexpression of p53 protein in inflammatory breast cancer. J Natl Cancer Inst 1993; 85:1765-1767.
42. Faille A, De Cremoux P, Extra JM, et al. p53 mutations and overexpression in locally advanced breast cancers. Br J Cancer 1994; 69:1145-1150.
43. Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000; 6:50-56.
44. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. P53 as a prognostic marker in inflammatory breast cancer. Clin Canc Res 2004; 10:6215-6221.
45. Miller LD, Smeds J, George J, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A 2005; 102:13550-13555. A 32-gene expression signature was identified on the basis of the transcript profile of 521 primary breast cancers, 58 of these were known to harbor p53 gene mutations. This p53 classifier was able to classify breast tumors and primary liver cancers according to their p53 mutational status. It had greater prognostic significance than p53 mutational analysis.
46. Bieche I, Lerebours F, Tozlu S, et al. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004; 10:6789-6795.
47. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64:8558-8565.
48. Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res 2005; 65:2170-2178. In this study expression profiles of 37 cases of IBC were compared to 44 non-IBC specimens. The five previously reported molecular subtypes could be identified.
49. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-752.
50. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100:8418-8423.
51. Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat 2005; 93:237-246. A distinct molecular signature based on the expression of 756 genes was identified. A high number of NF-κB target genes as well as upstream activators of NF-κB was found in the IBC profile.
52. Van Laere SJ, Van den Eynden GG, Van der Auwera I, et al. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling. Breast Cancer Res Treat 2006; 95:243-255. In this genome-wide expression analysis, IBC was mainly of either the basal or HER-2 subtype.
53. Dressman HK, Hans C, Bild A, et al. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res 2006; 12:819-826. In this study using the Affimetryx U133 plus2.0 Gene Chip a distinct expression profile for IBC was confirmed.
54. van Golen KL, Davies S, Wu ZF, et al. A novel putative low affinity insulin-like growth factor-binding protein LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 1999; 5:2511-2519.
55. van Golen KL, Wu ZF, Qiao XT, et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60:5832-5838.
56. Kleer CG, Zhang Y, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene 2002; 21:3172-3180.
57. Kleer CG, Zhang Y, Pan Q, et al. WISP3 and RhoC guanosine triphosphatase cooperate in the development of inflammatory breast cancer. Breast Cancer Res Treat 2004; 6:110-115.
58. Van den Eynden GG, Van Laere SJ, Van der Auwera I, et al. Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 2006; 95:219-228. The overexpression of either caveolin-1 or 2 is confirmed in cell lines and in human tissue samples of IBC. It is suggested to be caused by promotor hypomethylation.
59. Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. Nuclear factor-kappaB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-kappaB DNA binding. Clin Cancer Res 2006; 12:3249-3256. Overexpression of NF-κB transcription factors in IBC is confirmed by RT-PCR and DNA-binding experiments.
60. Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-kappaB transcriptional activity. Proc Natl Acad Sci U S A 2005; 102:2543-2548. A pathway selective ligand is described that antagonizes NF-κB functional activity but is devoid of estrogenic activity.
61. Holloway JN, Murthy S, El-Ashry D. A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-alpha downregulation in breast cancer cells: the role of nuclear factor-kappaB. Mol Endocrinol 2004; 18:1396-1410.